Minerva Neurosciences (NERV) Interest & Investment Income (2013 - 2026)
Minerva Neurosciences (NERV) posted Interest & Investment Income of $629602.0 for Q1 2026, up 15.2% on a QoQ basis from $546523.0 in Q4 2025, and up 297.76% year-over-year from $158288.0 in Q1 2025.
Minerva Neurosciences (NERV) Interest & Investment Income (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Interest & Investment Income history runs 14 years deep, the most recent figure standing at $629602.0 for Q1 2026.
- Quarterly Interest & Investment Income rose 297.76% year-over-year to $629602.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 32.32% YoY) and the FY2025 annual result came in at $948122.0, down 25.48% from the prior year.
- Interest & Investment Income was $629602.0 for Q1 2026 at Minerva Neurosciences, up from $546523.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $629602.0 in Q1 2026 and bottomed at $7417.0 in Q1 2022.
- A 5-year average of $284966.4 and a median of $313967.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 7941.69% — and 2025, when it slumped 66.03%.
- Minerva Neurosciences' Interest & Investment Income stood at $297060.0 in 2022, then increased by 20.81% to $358883.0 in 2023, then tumbled by 33.2% to $239724.0 in 2024, then jumped by 127.98% to $546523.0 in 2025, then grew by 15.2% to $629602.0 in 2026.
- Business Quant data shows NERV's Interest & Investment Income at $629602.0 in Q1 2026, $546523.0 in Q4 2025, and $106640.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Minerva Neurosciences | 185.26 Mn | 185.26 Mn | - | 629,602.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 629,602.00 |
| Dec 31, 2025 | 546,523.00 |
| Sep 30, 2025 | 106,640.00 |
| Jun 30, 2025 | 136,671.00 |
| Mar 31, 2025 | 158,288.00 |
| Dec 31, 2024 | 239,724.00 |
| Sep 30, 2024 | 313,967.00 |
| Jun 30, 2024 | 360,755.00 |
| Mar 31, 2024 | 357,908.00 |
| Dec 31, 2023 | 358,883.00 |
| Sep 30, 2023 | 348,681.00 |
| Jun 30, 2023 | 365,623.00 |
| Mar 31, 2023 | 364,218.00 |
| Dec 31, 2022 | 297,060.00 |
| Sep 30, 2022 | 180,091.00 |
| Jun 30, 2022 | 72,378.00 |
| Mar 31, 2022 | 7,417.00 |
| Dec 31, 2021 | 3,694.00 |
| Sep 30, 2021 | 4,156.00 |
| Jun 30, 2021 | 4,566.00 |